Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
IrAEs may serve as a predictive factor for the efficacy of the nivolumab + ipilimumab regimen in RCC patients. Special attention is needed for hepatotoxicity, as it can significantly impact survival outcomes.
Authors
- Renata Pacholczak‐Madej (ORCID: https://orcid.org/0000-0002-6535-4841)
- Paweł Blecharz (ORCID: https://orcid.org/0000-0001-5310-0054)
- Artur Drobniak
- Mirosława Püsküllüoğlu (ORCID: https://orcid.org/0000-0002-2647-9625)
- Aleksandra Grela-Wojewoda (ORCID: https://orcid.org/0000-0002-6727-8926)
- Jerzy Walocha (ORCID: https://orcid.org/0000-0001-8587-2315)
- Agnieszka Roman
- Jolanta Dobrzańska
- Łukasz Stokłosa
- Anna Bidas
- Daria Tusień-Małecka
Institutions
- Jagiellonian University (PL)
- University College of Tourism and Ecology (PL)
- National Institute of Oncology (HU)
- Holy Cross University (PL)
- Krakow Cardiovascular Research Institute (PL)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1186/s12885-024-13192-8
- Citations
- 9
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.77